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The pathological deposition of the transactive response DNA-binding protein of 43 kDa occurs in the majority (97%) of amyotrophic
lateral sclerosis and in around 45% of frontotemporal lobar degeneration cases. Amyotrophic lateral sclerosis and frontotemporal lobar
degeneration clinically overlap, presenting a continuum of phenotypes. Both amyotrophic lateral sclerosis and frontotemporal lobar de-
generation lack treatments capable of interfering with the underlying pathological process and early detection of transactive response
DNA-binding protein of 43 kDa pathology would facilitate the development of disease-modifying drugs. The real-time quaking-induced
conversion reaction showed the ability to detect prions in several peripheral tissues of patients with different forms of prion and
prion-like diseases. Despite transactive response DNA-binding protein of 43 kDa displays prion-like properties, to date the real-time
quaking-induced conversion reaction technology has not yet been adapted to this protein. The aim of this study was to adapt the real-
time quaking-induced conversion reaction technique for the transactive response DNA-binding protein of 43 kDa substrate and to ex-
ploit the intrinsic ability of this technology to amplify minute amount of mis-folded proteins for the detection of pathological transactive
response DNA-binding protein of 43 kDa species in the cerebrospinal fluid of amyotrophic lateral sclerosis and frontotemporal lobar de-
generation patients. We first optimized the technique with synthetic transactive response DNA-binding protein of 43 kDa–pre-formed
aggregates and with autopsy-verified brain homogenate samples and subsequently analysed CSF samples from amyotrophic lateral scler-
osis and frontotemporal lobar degeneration patients and controls. Transactive response DNA-binding protein of 43 kDa real-time quak-
ing-induced conversion reaction was able to detect as little as 15 pg of transactive response DNA-binding protein of 43 kDa aggregates,
discriminating between a cohort of patients affected by amyotrophic lateral sclerosis and frontotemporal lobar degeneration and age-
matched controls with a total sensitivity of 94% and a specificity of 85%. Our data give a proof-of-concept that transactive response
DNA-binding protein of 43 kDa is a suitable substrate for the real-time quaking-induced conversion reaction. Transactive response
DNA-binding protein of 43 kDa real-time quaking-induced conversion reaction could be an innovative and useful tool for diagnosis and
drug development in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The cerebrospinal fluid detection of transac-
tive response DNA-binding protein of 43 kDa pathological aggregates may be exploited as a disease biomarker for amyotrophic lateral
sclerosis and frontotemporal lobar degeneration patients.
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Introduction
In 2006, two different groups identified the transactive
response DNA-binding protein of 43 kDa (TDP-43) as
the major component of aggregates deposited in the cen-
tral nervous system (CNS) of patients affected by amyo-
trophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTLD) (Arai et al., 2006; Neumann et al.,
2006). TDP-43 pathology accounts for the majority of
ALS (97%) and for around 45% of FTLD (Ling et al.,
2013) cases. Subsequent studies showed abnormal accu-
mulation of TDP-43 in neurodegenerative disorders other
than FTLD and ALS, collectively named TDP-43 protei-
nopathies (Nonaka and Hasegawa, 2018). Amyotrophic
lateral sclerosis and FTLD clinically overlap, presenting
as a continuum phenotype, with ALS patients displaying
cognitive impairment or signs of frontotemporal dementia
(FTD) in approximately 50 and 15% of the cases, re-
spectively (Tsermentseli et al., 2012). Both ALS and FTD
display extensive clinical, pathological and genetic hetero-
geneity. Several genes showed to be linked to ALS and
FTD pathology (Ng et al., 2015). More specifically, the
presence of the C9orf72 expansion, mutations in
TARDBP, the gene encoding for TDP-43, and in the
Granulin gene, GRN, showed to be specifically related to
CNS pathological TDP-43 deposition (Saberi et al., 2015;
Mackenzie and Neumann, 2016; Turner et al., 2017).
Increasing evidence suggests that TDP-43 pathology could
progress following a prion-like mechanism (Maniecka
and Polymenidou, 2015). According to the prion-like hy-
pothesis, a mis-folded protein is able to interact with its
native isoform and to convert it in its pathological aber-
rantly folded form. This process can amplify and propa-
gate the aggregates, which can eventually be fragmented
to form the so-called ‘seed’ (i.e. the smallest amount of
the pathological protein able to replicate this process)
(Maniecka and Polymenidou, 2015). In keeping with this
view, TDP-43 aggregates appear to distribute progressive-
ly among axon-linked brain regions, suggesting the
spreading of the prion-like agent (Ravits and La Spada,
2009; Braak et al., 2013; Brettschneider et al., 2014;
Walker and Jucker, 2015; Ayers and Cashman, 2018)
and several studies have shown the intrinsic propensity of
TDP-43 to aggregate (Johnson et al., 2009; Furukawa
et al., 2011; Jiang et al., 2013). The ability of TDP-43
aggregates to act as seeds in vitro (Furukawa et al.,
2011; Nonaka et al., 2013; Smethurst et al., 2016) and
recently, also in vivo, has been shown (Porta et al.,
2018). Amyotrophic lateral sclerosis is a fatal neurodege-
nerative process usually diagnosed after 1 year from
symptoms onset when disease is well established and the
potential therapeutic window has passed (Feneberg et al.,
2018). Frontotemporal dementia diagnosis is challenging
and usually reached years after symptoms onset due to a
close similarity between behavioural changes in patients
with FTD and those seen in patients with psychiatric dis-
orders (BaNg et al., 2015). Both ALS and FTD lack
treatments capable of interfering with the underlying
pathological process. Accurate detection of TDP-43 path-
ology is therefore of utmost importance to select and en-
roll patients in clinical trials in the earliest disease phase.
In addition, pre-symptomatic screening would grant a
larger therapeutic window for disease-modifying drugs. A
consistent biochemical marker could also permit to moni-
tor disease progression and to evaluate the effect of spe-
cific treatments. Recently, real-time quaking-induced
conversion reaction (RT-QuIC) ante-mortem prion detec-
tion has proved as a robust technique for prion amplifi-
cation (Orru et al., 2015; Fairfoul et al., 2016;
Franceschini et al., 2017; Groveman et al., 2018). The
RT-QuIC showed the ability to detect prions in several
peripheral tissues of patients with different forms of prion
diseases (Orru et al., 2014; Orru et al., 2015;
Franceschini et al., 2017), misfolded amyloid beta (Ab)
oligomers in the cerebrospinal fluid (CSF) of patients
with Alzheimer Disease (AD) (Salvadores et al., 2014),
a-synuclein oligomers in the CSF of patients with
Parkinson’s disease and Lewy body dementia (Fairfoul
et al., 2016; Shahnawaz et al., 2017; Groveman et al.,
2018; van Rumund et al., 2019; Shahnawaz et al., 2020)
and tau in the CSF of patients with Pick’s disease (Saijo
et al., 2017). Despite TDP-43 displayed prion-like proper-
ties (Johnson et al., 2009; Furukawa et al., 2011; Jiang
et al., 2013; Nonaka et al., 2013; Smethurst et al., 2016;
Porta et al., 2018), to date, the RT-QuIC technology has
not yet been adapted to this protein. The aim of this
study was to adapt the RT-QuIC technique to the TDP-
43 substrate and to exploit this technology for the detec-
tion of pathological TDP-43 species in the CSF of ALS
and FTD patients. As a first step, we characterized the
kinetics of aggregation of full-length and truncated C-ter-
minal TDP-43 and we observed that in vitro produced
TDP-43 aggregates and patient-derived brain homoge-
nates (BHs) efficiently seeded the reaction with both sub-
strates. After this characterization, we selected the C-
terminal fragment of TDP-43 as the most efficient sub-
strate to perform the reaction. Finally, we collected and
screened CSF samples from ALS/FTD patients and age-
matched healthy controls. To increase the likelihood that
the collected CSF really contained TDP-43 seeds, we
focused our study on patients harbouring a pathological
mutation in one of the genes known to be related with
CNS TDP-43 pathology, TARDBP, GRN and C9orf72
(Saberi et al., 2015; Mackenzie and Neumann, 2016;




The pET-11a plasmid containing human TDP-43
(HuTDP-43(1-414)) coding sequence was purchased from
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GenScript. The truncated construct (HuTDP-43(263-414))
was obtained by deleting the DNA region encoding for
HuTDP-43 fragment 1-262 using mutagenesis.
Polymerase chain reaction was carried out using site-
directed mutagenesis kit (Agilent) with the following pri-
mers: 50-ttaagaaggagatatacatatgaaacacaacagcaaccgtcagc-30,
50-gctgacggttgctgttgtgtttcatatgtatatctccttcttaa-30. The pro-
tein production protocol was the same for both
full-length and the truncated form of the protein. The
construct was expressed in Escherichia coli BL21 (DE3)
cells (Stratagene). Freshly transformed overnight culture
was inoculated into Luria Bertani medium with 100 lg/
mL ampicillin. At 0.8 OD600, protein expression was
induced with isopropyl b-D-1-thiogalactopyranoside to a
final concentration of 1 mM. After overnight incubation
at 37C, cells were lysed by a homogenizer (PandaPLUS
2000) and inclusion bodies were washed in a buffer con-
taining 25 mM Tris-HCl, 5 mM ethylenediaminetetraacetic
acid (EDTA), 0.8% TritonX100, (pH 8) and then in bi-
distilled water (ddH2O) several times. Inclusion bodies
containing HuTDP-43(1-414) or HuTDP-43(263-414)
were dissolved in five volumes of 8 M guanidine hydro-
chloride (GdnHCl), loaded onto pre-equilibrated HiLoad
26/60 Superdex 200-pg column, and eluted in 25 mM
Tris–HCl (pH 8), 5 mM EDTA and 5 M GdnHCl at a
flow/rate of 1.5 mL/min. Protein refolding was performed
by dialysis against different refolding buffers [10 mM PBS
(pH ¼ 8) for the full-length protein; 10 mM PBS (pH ¼
8) or 25 mM Tris-HCl (pH ¼ 8) for the truncated frag-
ment] using a Spectrapor membrane. Purified proteins
were analysed by SDS-PAGE gel electrophoresis under
reducing conditions and Western blot.
Electrophoretic mobility shift assay
A specific sequence of RNA oligonucleotides, termed
AUG12 RNA, 50-GUGUGAAUGAAU-30, was purchased
from Sigma-Aldrich. In brief, 12.6 lM of AUG12 RNA
was mixed with 12.6 lM of HuTDP-43 or Bovine Serum
Albumin (BSA), as a control. Binding reactions (20 lL)
were incubated in water at room temperature (RT) for
20 min before loading onto an Agarose gel (1%) in 1
Tris–acetate–EDTA. Gels were run at 100–120 V for
45 min at 4 C.
Brain homogenates collection e
preparation
Post-mortem frozen frontal cortices samples of patients
with a confirmed neuropathological diagnosis of FTLD-
TDP associated with C9orf72 expansion (n¼ 1), FTLD-
TDP with mutation in the GRN gene (n¼ 1), FTLD-TDP
with unknown genetic background (n¼ 1) and of a nor-
mal control brain (n¼ 1) were collected. Brain samples
(0.5 g) were homogenized as previously described with
some modification (Nonaka et al., 2013). Briefly, samples
were homogenized in 2.5 mL of homogenization buffer
[HB: 10 mM Tris-HCl, 0.8 M NaCl, 1 mM EDTA, 1 mM
dithiothreitol (DTT), 1 protease and phosphatase inhibi-
tor cocktail tablets (Roche), pH 7.5]. Benzonase (Sigma)
was added (0.25 lL) to aliquots of 500 lL for each of
the lysates, which were then incubated in constant shak-
ing (400 rpm) for 10 min at 37C. After this, Sarkosyl
was added to each aliquot (final concentration, 1%) and
samples were then incubated for 20 min at 37C under
shaking (400 rpm). Ethanol was added to a final concen-
tration of 20% and samples were incubated in constant
shaking (400 rpm) for 10 min at 37C. Samples were cen-
trifuged at 150 000g for 60 min at RT. Supernatants were
discarded, and pellets were suspended in 300 lL PBS by
sonication and centrifuged at 150 000g for 60 min at RT.
The resulting pellets were suspended in 50 lL of ddH2O
by sonication and diluted at 103 v/v in ddH2O.
Cerebrospinal fluid sample
collection and study population
Informed consent was given by all study participants or
their next of kin. The CSF samples were collected by lum-
bar puncture after a standard procedure, centrifuged at
1000g for 10 min and stored in polypropylene tubes at
80C, until analysis. Table 1 summarizes the characteris-
tics of the study population. We retrospectively analysed
CSF samples from a total of 36 ALS/FTD patients (21
males and 15 females) harbouring a pathological mutation
in one of the genes known to be related to CNS TDP-43
deposition (i.e. C9orf72, TARDBP, GRN) (Supplementary
Table 1). Samples were provided by several Italian institu-
tions and specifically from: the Department of
Neuroscience, Rehabilitation, Ophthalmology, Genetics,
Maternal and Child Health, University of Genoa, IRCCS
Ospedale Policlinico, San Martino, Genoa; the ‘Rita Levi
Montalcini’ Department of Neuroscience, University of
Turin, Turin; the Fondazione IRCCS Istituto Neurologico
Carlo Besta, Unit of Neurology 5 and Neuropathology,
Milan; the Department of Neurology and Laboratory of
Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan;
the Molecular Markers Laboratory, IRCCS Istituto Centro
San Giovanni di Dio Fatebenefratelli, Brescia; the
Department of Clinical and Experimental Sciences,
Neurology Unit, University of Brescia, Brescia and from
the Clinical Unit of Neurology, Department of Medicine,
Surgery and Health Sciences, Neurology Unit, University
Hospital and Health Services of Trieste, University of
Trieste, Trieste. We collected 19 CSF samples from patients
with a C9orf72 expansion, three from patients with a
TARDBP mutation and 14 GRN-mutated patients. The
C9orf72 population was composed of 10 ALS patients
(two of them with associated signs of cognitive decline, not
reaching criteria for FTD diagnosis), eight FTD-affected
patients and one patient with an AD-like phenotype (all of
them without signs of motor neuron involvement). All
TARDBP-mutated patients were clinically diagnosed as
ALS. The diagnoses of ALS and FTD were made according
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to current diagnostic criteria (Brooks et al., 2000;
Rascovsky et al., 2012). Among the GRN population, one
sample was derived from a pre-symptomatic patient with-
out any clinical sign. Except for this patient, all patients in
the GRN population presented with cognitive impairment.
In total, 10 GRN patients were classified as FTD and
more specifically, 8 were diagnosed as behavioural variant
FTD (bv-FTD) and 2 as agrammatic variant of primary
progressive aphasia according to current re-defined clinical
criteria (Gorno-Tempini et al., 2011; Rascovsky et al.,
2012). Three GRN patients were not diagnosed as FTD.
One had a clinical diagnosis of cortico-basal syndrome
(CBS), one of mild cognitive impairment (MCI) and one
was diagnosed as AD according to current clinical diagnos-
tic criteria (McKhann et al., 2011; Armstrong et al., 2013).
We also collected CSF from 27 age-matched control
patients (14 males and 13 females), which underwent a
lumbar puncture to exclude a neurological disease. In none
of these cases was the suspected disease, ALS, FTD, or any
other neurodegenerative disorder. Leucocyte count, glucose,
total protein, blood pigments, lactate and oligoclonal IgG
bands were all normal in the analysed CSF.
In vitro generation of recombinant
human TDP-43 aggregates
In vitro aggregation reactions of human TDP-43 were
performed in 200 lL of reaction mix in black, clear-bot-
tom, 96-well microplates. The reaction mix contained
10 mM PBS at pH 6.8, 5 mM DTT, 100 mM NaCl,
50 lM thioflavin T (ThT), 0.002% of sodium dodecyl
sulfate (SDS) and 2 mg/mL of HuTDP-43. After sealing,
the plate was incubated at 40C, over a period of 50 h
with intermittent cycles of shaking (60 s, 400 rpm, dou-
ble-orbital) and rest (60 s). For HuTDP-43(263-414) ag-
gregation, the reaction mix contained 10 mM PBS at pH
7.8, 100 mM NaCl, 10 lM ThT, 0.002% of SDS and
0.2 mg/mL of HuTDP-43(263-414). After sealing, the
plate was incubated at 40C, over a period of 24 h with
intermittent cycles of shaking (60 s, 400 rpm, double-or-
bital) and rest (60 s). All reactions were performed in a
FLUOstar OMEGA reader (BMG Labtech, Germany) and
fluorescence intensity, expressed as relative fluorescence
unit (RFU), was taken every 30 min using 450 6 10 nm
(excitation) and 480 6 10 nm (emission) wavelengths and
a gain of 1000. All solutions were filtered before use
with 0.22 lm sterile filters. Recombinant proteins were
subjected to 2 h of centrifugation at 186 000g at RT be-
fore their use in the reaction. The addition of a 3-mm
glass bead (Sigma) was required to sustain protein aggre-
gation. The final product of these reactions was collected
by ultracentrifugation at 100 000g for 1 h and suspended
by sonication in the same starting volume of ddH2O and
used as synthetic seed. Protein aggregates were analysed
by atomic force microscopy.
TDP-43 RT-QuIC optimization
All RT-QuIC reactions were performed in 200 lL of reac-
tion mix in black, clear-bottom, 96-well microplates. To
optimize the reaction for HuTDP-43 and its truncated
fragment HuTDP-43(263-414), we used different experi-
mental protocols. The RT-QuIC reaction mix contained
10 mM PBS at pH 6.8, 5 mM DTT, 100 mM NaCl,
25 lM ThT, 0.002% of SDS and 1 mg/mL of HuTDP-43.
After sealing, the plate was incubated at 40 C, over a
Table 1 Characteristics of CSF study population
Characteristic C9orf72 TARDBP GRN Totals patients CTRLs
Men, n. (%) 11 (58) 2 (67) 8 (57) 21 (58) 14 (52)
Age at CSF collection,
y. (6SD)
59 6 10 58 6 16 63 6 8 60 6 10 65 6 13
Age at onset, y.
(6SD)
58 6 9 55 6 15 59 6 4 58 6 9 N.A.
Onset-CSF collection,
m. (6SD)
22 6 17 32 6 19 22 6 9 23 6 15 N.A.
Pure ALS phenotype,
n.
8 3 _ 11 N.A.
ALS plus cognitive de-
cline n.
2 _ _ 2 N.A.
Pure FTD, n. 8 _ 10 18 N.A.
CBS, n. _ _ 1 1 N.A.
MCI, n. _ _ 1 1 N.A.
AD, n. 1 _ 1 2 N.A.
Pre-symptomatic car-
rier, n.
_ _ 1 1 N.A.
Total, n. 19 3 14 36 27
Positive in RT-QuIC,
n. (%)
18 (95) 3 (100) 13 (93) 34 (94) 4 (15)
Data are presented as numbers (n.), (percentages) and means (6SD). The onset-CSF collection time was calculated in months and refers to the time passed between the onset of
disease and the collection of the CSF sample. y.: years; m.: months; CTRLs: age-matched control patients; N.A.: not applicable. CSF: cerebrospinal fluid; ALS: amyotrophic lateral
sclerosis; FTD: frontotemporal dementia; CBS: cortico-basal syndrome; MCI: mild cognitive impairment; AD: Alzheimer disease; RT-QuIC: real-time quacking-induced convertion.
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period of 50 h with intermittent cycles of shaking (60 s,
400 rpm, double-orbital) and rest (60 s). For HuTDP-
43(263-414) aggregation, the reaction mix contained
10 mM PBS at pH 7.8, 100 mM NaCl, 10 lM ThT,
0.002% of SDS and 0.2 mg/mL of HuTDP-43(263-414).
After sealing, the plate was incubated at 40C, over a
period of 24 h with intermittent cycles of shaking (60 s,
400 rpm, double-orbital) and rest (60 s). We also opti-
mized another reaction condition with HuTDP-43(263-
414) in terms of reaction buffer and shaking protocol.
The reaction buffer was changed as follows: 40 mM Tris
(pH 8), 0.5 M GdnHCl (pH 8), 10 lM ThT, 0.002% of
SDS and 0.05 mg/mL of HuTDP-43(263-414). After seal-
ing, the plate was incubated at 40C, over a period of
50 h exposed to 15 s of shaking every 30 min at 100 rpm
(double-orbital). Reactions were performed in a
FLUOstar OMEGA reader (BMG Labtech, Germany) and
the fluorescence intensity, expressed as RFU, was taken
every 30 min using 450 6 10 nm (excitation) and
480 6 10 nm (emission) wavelengths, with a bottom read
and a gain of 1000. All solutions were filtered before use
with 0.22-lm sterile filters. Recombinant proteins were
subjected to 2 h of centrifugation at 186 000g at RT be-
fore their use in the reaction. The addition of a 3-mm
glass bead (Sigma) was required to sustain protein aggre-
gation. Reactions were seeded with 20 lL of 103 diluted
BH samples.
CSF TDP-43 seed detection with
RT-QuIC
For CSF TDP-43 seed detection, 6 lL of each CSF sample
was added to 194 lL of reaction mix in black, clear-bot-
tom, 96-well microplates. Samples were tested in tripli-
cate. To test CSF samples, we used our optimized
protocol for HuTDP-43(263-414). The RT-QuIC reaction
mix contained 40 mM Tris at pH 8, 0.5 M GdnHCl (pH
8), 10 lM ThT, 0.002% of SDS and 0.05 mg/mL of
HuTDP-43(263-414). All solutions were filtered before
use with 0.22-lm sterile filters. Recombinant HuTDP-
43(263-414) was centrifuged 2 h at 186 000g at RT to re-
move pre-formed aggregates before its use in the reaction.
After sealing, the plate was incubated in a FLUOstar
OMEGA reader (BMG Labtech, Germany) at 40C, over
a period of 72 h. Every 30 min, the reaction was exposed
to 15 s of shaking at 100 rpm (double-orbital). The fluor-
escence intensity of the reaction was taken every 30 min
using 450 6 10 nm (excitation) and 480 6 10 nm (emis-
sion) wavelengths, with a bottom read and a gain of
1000. The addition of a 3-mm glass bead (Sigma) was
required to sustain protein aggregation. A CSF sample
was considered positive in a single experiment if two out
of three well reached a defined RFU threshold (five times
their starting fluorescence value) before a time threshold
of 56.6 h (see Lag-phase threshold definition section). To
be considered as a definite positive, each sample had to
test positive in two out of the three independent
experiments. To investigate the detection power of our
technique, we serially diluted (till 106) the in vitro
obtained HuTDP-43(263-414) aggregates in a previously
screened true-negative CSF sample which was analysed




For each sample, 50 lL of re-suspended PureProteome
Protein A magnetic beads (MerkMillipore-LSKMAGA02)
were used. After three washes with 500 lL of PBS 1
0.1% Tween-20, beads were re-suspended in 100 lL of
PBS 1 0.1% Tween-20 and added to a cocktail com-
posed of 10 lg of rabbit polyclonal anti-C-terminal
(Sigma-Aldrich-T1580) and 10 lg of rabbit polyclonal
anti-N-terminal (Sigma-Aldrich SAB4200006) TDP-43
antibodies. After 30 min of incubation at RT in constant
agitation, the buffer was discarded and 60 lL of each
sample was incubated with the antibody-coated beads for
24 h at 4C with constant mixing. Depleted samples were
subsequently analysed with the optimized TDP-43 RT-
QuIC protocol.
In vitro generation of recombinant
human a-synuclein (a-syn) and tau
K18 aggregates
Recombinant full-length human a-syn and tau K18 frag-
ment were provided from collaborators in our group.
Expression and purification of recombinant tau K18 frag-
ment and of full-length a-syn were performed as
described previously (Barghorn et al., 2005; Huang et al.,
2005). In vitro fibrillization reactions were performed at
37C with intermittent cycles of shaking (50 s, 400 rpm,
double-orbital) and rest (10 s) in a FLUOstar OMEGA
reader (BMG Labtech, Germany). Newly formed aggre-
gates were pelleted by ultracentrifugation (186 000 g for
1 h at 4C) and re-suspended in sterile ddH2O. Before
their use, aliquots were sonicated for 3 min in an ultra-
sonic bath (Branson 2510).
Atomic force microscopy analysis
TDP-43 in vitro-generated aggregates were dialysed
against bi-distilled water at RT overnight and then sub-
jected to atomic force microscopy (AFM) imaging. A vol-
ume of 10 lL was dropped onto freshly sliced muscovite
mica (V-1) and incubated for 15 min for sample adhe-
sion. The same volume of absolute ethanol was added,
allowing the drop to evaporate. The sample was left to
dry at RT and subjected to AFM imaging (NT-MDT
Solver-Pro) in semi-contact mode, using commercial sili-
con cantilevers (NSG03, NT-MDT Spectrum Instruments,
<10 nm radius of curvature, spring constant of
1.74 Nm1).
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Lag-phase threshold definition
We performed the RT-QuIC reaction with all control and
patient samples in three separate experiments, each one
in triplicate, and we collected for each well of each ex-
periment the time needed to reach an arbitrary fluores-
cence threshold that we set at five times the initial
fluorescence value of each well. We then calculated the
median lag-phase time for each triplicate and, subsequent-
ly, the median of the medians resulting from the three in-
dependent experiments (that we will call ‘total median
time’). This procedure provided a single and informative
number for each patient (i.e. the total median time).
After this, we plotted the distribution of total median
times and from the observation of these distributions we
derived the lag-phase threshold of 56.6 h (Supplementary
Fig. 2A). In order to address the risk of overfitting, we
cross-validated our data. For a 1000 times, we simulated
to split the data set into a training set comprising 50%
of the data, (i.e. 14 controls and 18 patients) and a test-
ing set (i.e. the remaining 50%). For each simulation, we
defined the threshold based on the training set and
applied it to the testing set to compute the cross-validated
accuracy. To illustrate how the choice of the lag-phase
threshold would influence the true-positive rate and false-
positive rate numbers, we built the receiver operating
characteristic curve which highlights the points with the
highest accuracies (Supplementary Fig. 2B).
Statistical analysis
For the correlation analysis between baseline patient
characteristics and RT-QuIC positive results, we used dif-
ferent tests. For binary features, we performed Welch
two-sample t-tests, for categorical baseline characteristics,
we used ANOVAs, and for continuous features, both lin-
ear models and ANOVAs. All statistical analyses were
conducted in R and figures were produced using the
package ggplot2 (Wickham, 2009). All RT-QuIC graphs
were produced with GraphPad (PRISM 7.0a) and the re-
spective figures were generated with Inkscape 1.0.
Data availability
The data supporting the findings of this study are avail-
able from the corresponding author on request.
Results
Adaptation of RT-QuIC to TDP-43
amplification
The first attempt to adapt the RT-QuIC methodology to
TDP-43 was to obtain high amounts of soluble recombin-
ant protein to be used as the substrate for the reaction.
After several trials, we optimized an efficient protocol for
full-length TDP-43 (HuTDP-43) production and refolding
(Materials and methods section). After refolding, the re-
combinant protein product was highly pure, devoid of
signs of degradation and functional in terms of its RNA-
binding activity (Supplementary Fig. 1). The second critic-
al step was to identify the best conditions for HuTDP-43
aggregation. In fact, several factors were modified to im-
prove the efficiency and reproducibility of TDP-43 RT-
QuIC, such as protein concentration, temperature, pH of
the reaction and shaking protocol. Figure 1A shows the
aggregation kinetics profile of HuTDP-43. The aggrega-
tion curve is characterized by a lag phase of about 15–
20 h, followed by a slow and progressive increase in ThT
fluorescence emission and a subsequent plateau reached
after around 30–35 h (Fig. 1a, black line). We collected
the final product of this reaction and employed it as a
synthetic aggregate. When the synthetic seed was added
to the reaction, we observed a clear anticipation of the
lag phase associated with an increase in the amount of
ThT fluorescence emission (Fig. 1A, green line).
Interestingly, the aggregation profile observed in our ex-
perimental setting, substantially differed from those
observed in the previous studies where the aggregation
curve of HuTDP-43 completely lacked a lag phase
(Johnson et al., 2009; Furukawa et al., 2011; Jiang et al.,
2013). To characterize the aggregates used as synthetic
seeds, we subjected them to AFM analysis, observing that
they mainly displayed features of amorphous aggregates,
lacking fibrillary structures (Fig. 1C). Since the C-terminal
domain of TDP-43 is known to be more aggregation-
prone (Saini and Chauhan, 2011; Budini et al., 2012),
we produced a recombinant C-terminal fragment from
amino acid 263 to the end of the protein (HuTDP-
43(263-414)). Also in this case the final protein product
was pure and devoid of signs of degradation
(Supplementary Fig. 1). We analysed its aggregation
properties and observed a typical prion-like aggregation
kinetics (Fig. 1B, black line). Compared to HuTDP-43,
HuTDP-43(263-414), aggregation curve showed a shorter
lag phase and higher values of ThT fluorescence emission
(Fig. 1). The final product of this reaction was also very
efficient as synthetic seed (Fig. 1B, green line). The AFM
analyses of HuTDP-43(263-414) aggregates differed sub-
stantially from those of HuTDP-43, presenting typical fi-
brillary features (Fig. 1D). We considered that the
different aggregation profiles of HuTDP-43 and HuTDP-
43(263-414) were strictly related to the different final
conformation acquired by their aggregates (Fig. 1). Only
a fraction of HuTDP-43 would acquire b-sheet conform-
ation, thus binding ThT, whereas HuTDP-43(263-414) is
readily converted in b-sheet-enriched fibrils.
TDP-43 RT-QuIC optimization
To investigate which substrate (HuTDP-43 or HuTDP-
43(263-414)) was more efficient to detect biological TDP-
43 aggregates, we seeded the reaction with a small pool
of pathological confirmed patient-derived BHs. Both
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HuTDP-43 and HuTDP-43(263-414) were efficiently
seeded by three positive BH samples, whereas a negative-
control BH at the same dilution (103) did not affect the
aggregation kinetics of the reaction (Fig. 2A, B). This
trial indicated that both proteins were suitable substrates
for the amplification assay. However, since the reaction
with HuTDP-43 required higher amounts of substrate,
we selected HuTDP-43(263-414) as the most efficient
product to perform further analyses. Another relevant
point for the optimization of the TDP-43 RT-QuIC tech-
nology, as a tool to detect TDP-43 seeds, was to obtain
a slower aggregation profile of the substrate, to provide
the optimal time window for discrimination between
positive and negative samples. For this purpose, we modi-
fied the reaction buffer with the addition of GdnHCl and
the removal of NaCl. We also reduced the amount of the
HuTDP-43(263-414) substrate from 0.2 to 0.05 mg/mL
and modified the aggregation protocol (only 15 s of
shaking every 30 min, at 100 rpm). After this optimiza-
tion, all positive BH samples maintained their seeding ac-
tivity but, as expected, with a slower aggregation kinetics
(Fig. 2C).
CSF TDP-43 seed detection with
RT-QuIC
Since our final aim was to screen CSF samples, it was
also important to take into account the effect of the CSF
material to the reaction. When small aliquots of CSF
(control or disease) were added to the reaction, we
observed an inhibition of HuTDP-43(263-414) aggrega-
tion. This was expected, since this CSF inhibiting effect
was also experienced by other groups (Shahnawaz et al.,
2017). For this reason, the threshold that we set to dis-
criminate between positive and negative CSF samples,
derived from the comparison between all our CSF
Figure 1 Aggregation kinetics of recombinant TDP-43 and AFM seeds characterization. Purified seed-free recombinant HuTDP-43
(2 mg/mL) (A) and HuTDP-43(263-414) (0.2 mg/mL) (B) were induced to aggregate by alternating cycles of 60 s (s) of shaking and 60 s of
incubation at 40C (black lines). The final product of their aggregation was collected and efficiently employed as synthetic seed (green lines). ThT
fluorescence is plotted against time. Each graph has a specific range of ThT fluorescence values and duration of a given reaction. The experiment
was performed in triplicate and each replica was performed three times. Curves represent means for all experimental replicates and bars
indicate the standard deviations (SD). (C, D) AFM analysis of TDP-43 aggregates. HuTDP-43 aggregates showed features of amorphous
aggregates (C), whereas HuTDP-43(263-414) (D) acquired a fibrillary structure after aggregation.
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samples (disease and control) (Supplementary Fig. 2),
since the spontaneous aggregation of the substrate (i.e.
the reaction performed with the substrate alone without
addition of CSF aliquots) was not a reliable parameter.
CSF samples collected from C9orf72 expansion (n¼ 19),
TARDBP (n¼ 3), GRN (n¼ 14) mutation carriers and
age-matched controls (n¼ 27) (for clinical details, see
Table 1) were analysed by means of RT-QuIC to investi-
gate their effects on the kinetics of HuTDP-43(263-414)
aggregation. We found that 18 out of 19 C9orf72, 3 out
of 3 TARDBP and 13 out of 14 GRN samples efficiently
seeded the RT-QuIC reaction (Fig. 3A, B, C, E). Among
age-matched controls, we observed four positive results
(Fig. 3D, E). These values correspond to a global sensitiv-
ity of 94% and specificity of 85%. In order to address
the risk of overfitting, we cross-validated our data. The
accuracy values predicted by the cross-validation model
were 92 and 84% of sensitivity and specificity, respective-
ly, confirming the observed experimental measurements.
Among the GRN group, notably, one positive sample
was derived from a healthy carrier of the mutation.
There was no significant correlation between baseline
characteristics (age at CSF collection, time between dis-
ease onset and CSF collection, ALS, FTD, ALS plus FTD
or cognitive decline phenotypes) and RT-QuIC positive
results. The one C9orf72 and the one GRN-negative
patients did not display any difference compared to the
other samples, possibly explaining their low seeding effi-
ciency. More in detail, they presented clinical features
(ALS without cognitive impairment and bv-FTD, respect-
ively), age at CSF collection (45 and 58 years, respective-
ly) and delay from onset to CSF collection (24 months
for both patients) comparable to the rest of the patient
population (Table 1). Regarding the four unexpected
positive results among control patients (i.e. false-positive
samples), we did not observe any specific feature impli-
cated in their seeding ability. All four patients were age-
matched against the study population and did not present
any clinical condition related to neurodegeneration.
Leucocyte count, glucose, total protein, blood pigments,
lactate and oligoclonal IgG bands were all normal in
their CSF. To investigate if the seeding activity of positive
CSF samples was driven by the presence of TDP-43
aggregates, we used magnetic beads coated with a cock-
tail composed of two anti-TDP-43 antibodies to immune-
deplete one true positive (i.e. a CSF sample from a pa-
tient which tested positive in the TDP-43 RT-QuIC assay)
and two false-positive samples (i.e. samples from two
controls which resulted positive in our analysis). After de-
pletion, the true-positive sample had an almost abolished
seeding activity and tested negative (Fig. 4A). This sug-
gests that the procedure was able to deplete it from the
majority of TDP-43 aggregates. Regarding the depleted
false-positive samples, one of them became negative,
whereas the other one remained positive, even if
Figure 2 RT-QuIC analysis of BH samples. In brief, 20 lL of
sonicated and diluted (103) BHs collected from three FTLD-TDP
patients (BH*, purple lines) and one CTRL patient (CTRL BH, black
line) were added to purified seed-free recombinant HuTDP-43
(1 mg/mL) (A) and HuTDP-43(263-414) (0.2 mg/mL) (B) and
analysed by means of RT-QuIC. The reaction was exposed to 60 s
of shaking and 60 s of rest. All positive BHs efficiently seeded the
reaction, whereas the negative control BH at the same dilution
(103) did not affect the aggregation kinetics of the reaction. (C)
Optimized protocol for BH analysis using purified seed-free
HuTDP-43(263-414) (0.05 mg/mL) as substrate with a different
reaction buffer (no NaCl, Gdn-HCl added) and a modified protocol
(shaking at 100 rpm for 15 s every 30 min at 40C). ThT
fluorescence intensity was plotted against time. Each graph has a
specific range of ThT fluorescence values and duration of a given
reaction. The experiment was performed in triplicate and each
replica was performed three times. Curves represent means for all
experimental replicates and bars indicate the standard deviations
(SD).
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Figure 3 RT-QuIC analysis of ALS and FTLD-TDP CSF samples. In brief, 6 lL of undiluted CSF collected from patients with a known
pathological TDP-43-related mutation (C9orf72, green lines, TARDBP, magenta lines, GRN, blue lines) and from age-matched controls (CTRLs,
orange lines) were added to purified seed-free recombinant HuTDP-43(263-414) (0.05 mg/mL) and analysed by means of RT-QuIC with the
optimized protocol (shaking at 100 rpm for 15 s every 30 min at 40C). ThT fluorescence intensity is plotted against time. Dotted black lines
represent the ThT fluorescence and lag-phase thresholds. In the first four panels (A–D) the curves for each group are shown separately,
whereas in (E) samples are shown all together. The experiment was performed in triplicate and each replica was performed three times. Each
curve shows the median aggregation curve for each sample.
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presenting a diminished intensity of ThT fluorescence
emission (Figure 4B). This implies that some false-positive
results may be associated with the presence of TDP-43
aggregates in the CSF of asymptomatic patients, whereas
some others may be related to the presence/absence of
other factors capable of interfering with the reaction in a
non-specific way.
Performance of TDP-43 RT-QuIC
with tau and a-synuclein (a-syn)
aggregates
To investigate the performance of TDP-43 RT-QuIC with
aggregates composed of other pathological amyloids, we
tested the seeding ability of pre-formed tau K18 and a-
syn fibrils. Since we wanted to replicate the same experi-
mental settings that we used for the CSF analysis, we
diluted tau K18 or a-syn fibrils in a previously screened
negative CSF from a control patients. The CSF sample
spiked with 1.5 ng of tau K18 or a-syn fibrils presented
no seeding activity in the TDP-43 RT-QuIC (Fig. 5).
Notably, when the same amount of TDP-43 in vitro-
obtained fibrils (1.5 ng) was diluted in the same negative
CSF, the sample resulted positive (Fig. 5). Tau K18 and
a-syn aggregates presented an efficient seeding activity
when tested with their respective tau or a-syn RT-QuIC
assays. These results suggest that, under these experimen-
tal conditions, TDP-43 RT-QuIC is not susceptible to the
presence of tau or a-syn amyloids.
RT-QuIC detection of aggregated
TDP-43
To measure the capabilities of RT-QuIC detection of
aggregated TDP-43, we added different dilutions of the
in vitro-obtained HuTDP-43(263-414) aggregates to a
previously screened negative CSF sample and tested the
Figure 4 RT-QuIC analysis of immune-depleted CSF
samples. One true-positive (TP) and two false-positive (FP) CSF
samples were immune-depleted of TDP-43 aggregates using
magnetic beads coated with a cocktail of two anti-TDP-43
antibodies directed against two different epitopes of the protein.
Samples before and after immune-depletion were added to purified
seed-free recombinant HuTDP-43(263-414) (0.05 mg/mL) and
analysed by means of RT-QuIC (shaking at 100 rpm for 15 s every
30 min at 40C). ThT fluorescence intensity is plotted against time.
Dotted black lines represent the ThT fluorescence and lag-phase
thresholds. (A) After depletion, the true-positive sample tested
negative (blue dashed line). After depletion, one of the false-
positive samples became negative (red dashed line), whereas the
other one remained positive, even if presenting a diminished
intensity of ThT fluorescence emission (yellow dashed line). The
experiment was performed in triplicates and each replica was
performed three times. The image represents the median
aggregation curve for each sample.
Figure 5 Performance of TDP-43 RT-QuIC with tau and a-
synuclein aggregates. A previously screened negative CSF
sample was spiked with 1.5 ng of tau K18, a-syn or TDP-43–pre-
formed seeds. The CSF samples spiked with tau K18 (blue line) or
a-syn (yellow line) fibrils presented no seeding activity in the
optimized TDP-43 RT-QuIC. TDP-43 preformed aggregates diluted
in the same negative CSF efficiently seeded the reaction (green
line). Protocol details: 0.05 mg/mL of purified seed-free
recombinant HuTDP-43(263-414) substrate; shaking at 100 rpm for
15 s every 30 min at 40C. ThT fluorescence intensity is plotted
against time. The experiment was performed in triplicates and each
replica was performed three times. The image represents the
median aggregation curve for each sample.
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seeding activity of these products. We observed that our
assay was able to detect as little as 15 pg of TDP-43
pathological aggregates (Fig. 6). Since we knew the exact
amount of the diluted TDP-43 aggregates, this was the
most accurate method in our hands to characterize a
dose–response correlation for the optimized RT-QuIC.
Furthermore, standard detection techniques failed to
quantify the content of pathological hyperphosphorylated
TDP-43 in CSF samples from our cohort. For this reason,
a dose–response analysis on patient-derived CSF was not
feasible. Since our dose–response characterization was
performed with the use of synthetic aggregates, which
may or may not represent in vivo-circulating TDP-43 spe-
cies, further experiments are needed to verify if this esti-
mation also applies to patient-derived samples.
Discussion
Despite many efforts, ALS and FTD still lack treatments
that are capable of interfering with the underlying patho-
logical process. One reason is the absence of an early
diagnostic biomarker able to detect the disease before ir-
reversible neuronal damage has occurred. In fact, like
amyloid b-deposition in AD (Bateman et al., 2012), it is
possible that the formation and accumulation of patho-
logical aggregates of mis-folded TDP-43 species could
also begin decades before symptoms onset. As a conse-
quence, patients are usually enrolled in trials in advanced
clinical phases when neuronal damage and the neurodege-
nerative process have already started, thus decreasing the
potential efficacy of tested compounds. The availability of
a reliable biochemical marker could also help in monitor-
ing disease progression in the evaluation of response to a
specific treatment. Our approach to detect the presence
of pathological TDP-43 species in the CSF of ALS and
FTD patients was to exploit the RT-QuIC intrinsic ability
to amplify minute amount of mis-folded proteins. Since
this technology proved to efficiently perform with prions
and several other prion-like proteins (Orru et al., 2014;
Salvadores et al., 2014; Orru et al., 2015; Fairfoul et al.,
2016; Franceschini et al., 2017; Saijo et al., 2017;
Shahnawaz et al., 2017; Groveman et al., 2018; van
Rumund et al., 2019) and since TDP-43 displayed prion-
like features, we aimed at optimizing it for TDP-43. We
report that recombinant human TDP-43 is a suitable sub-
strate to perform the RT-QuIC reaction. We describe an
efficient protocol for a large-scale production and purifi-
cation of both full-length and truncated TDP-43, essential
to set up and perform the RT-QuIC technique. As a first
step in TDP-43 RT-QuIC adaptation, we used the final
products of aggregation of both HuTDP-43 and HuTDP-
43(263-414) proteins which efficiently seeded the reaction
and we subsequently moved to the study of a small sub-
set of BHs derived from autopsy-verified TDP-43-positive
cases. We selected TDP-43 C-terminal fragment as the
best substrate for a large-scale sample screening. We col-
lected CSF samples from patients harbouring a patho-
logical mutation in one of the genes known to cause
TDP-43 deposition in the CNS. This approach implied at
least two advantages: (i) even without a neuropathologic-
al confirmation, the presence of a known pathological
TDP-43-related mutation increased the likelihood that
those CSF contained toxic TDP-43 species; (ii) analysing
CSF from patients with a TDP-43-related mutation
reduced the pathological uncertainty related to heteroge-
neous clinical presentations. This second observation
explains our decision to collect CSF also from patients
with a clinical diagnosis different from classical ALS and
FTD, as long as they harboured a TDP-43-related patho-
logical mutation. Our data suggest that TDP-43 RT-
QuIC is able to discriminate between a cohort of patients
affected by ALS and FTD and age-matched controls with
a total sensitivity of 94% and a specificity of 85%,
detecting as little as 15 pg of TDP-43 seed. Among the
GRN group, we also tested one pre-symptomatic carrier
that resulted positive. This patient, to date, remains
asymptomatic and is under clinical follow-up. Since the
co-deposition of TDP-43 and other pathological proteins
occurs frequently in many neurodegenerative disorders
(Amador-Ortiz et al., 2007; Freeman et al., 2008; Lin and
Dickson, 2008; Arai et al., 2009; Josephs et al., 2016;
Figure 6 Performance of TDP-43 RT-QuIC with TDP-43
CSF. Different dilutions of in vitro-obtained HuTDP-43(263-414)
aggregates were added to a previously screened negative CSF
sample. TDP-43 RT-QuIC was able to detect as little as 15 pg of
TDP-43 pathological aggregates. Protocol details: 0.05 mg/mL of
purified seed-free recombinant HuTDP-43(263-414) substrate;
shaking at 100 rpm for 15 s every 30 min at 40C. ThT fluorescence
intensity is plotted against time. Dotted black lines represent the
ThT fluorescence and lag-phase thresholds. The experiment was
performed in triplicate and each replica was performed three times.
The image represents the median aggregation curve for each
sample.
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Berning and Walker, 2019), we considered inaccurate to
use CSF samples derived from patients affected by other
neurodegenerative diseases to assess the presence of cross-
seeding. To overcome this potential limitation and to
maintain the experimental settings of the CSF-optimized
RT-QuIC technology, we diluted 1.5 ng of tau K18 or
a-syn pre-formed aggregates in a negative CSF sample
and we observed no cross-seeding activity. Our study is
not without limitations. First, sensitivity and specificity of
our protocol are lower than desired. According to the
analysis on depleted false-positive samples, it seems that
false positivity could be related to multiple factors. The
fact that one false-positive sample became negative after
the TDP-43 depletion protocol suggests that at least some
of the observed false-positive results could be due to the
presence of TDP-43 aggregates in the CSF of asymptom-
atic patients. Since we do not possess neuropathological
confirmation for the examined samples, it is not possible
to exclude that we have detected the presence of patho-
logical TDP-43 seeds in healthy patients who would
eventually develop a TDP-43-related disorder during their
life span. In this regard, it should be mentioned that sev-
eral reports observed the presence of age-dependent TDP-
43 deposition in a discrete proportion of cognitively
impaired but also healthy patients (Geser et al., 2010;
Uchino et al., 2015). The fact that one false-positive sam-
ple remained positive after depletion also suggests that
some of the observed false-positive results might be in-
trinsically related to CSF composition. The CSF samples,
in fact, may differ in the presence or absence of specific
molecules capable of modifying the kinetics of aggrega-
tion of the substrate in a non-specific way, independent
of the presence of aggregates. A preparation method able
to remove, or at least limit, possible TDP-43 interactors
in the analysed samples needs to be implemented to over-
come this potential limitation. We would also like to test
other patient-derived tissues, to evaluate their characteris-
tics and seeding efficiency. A second limitation of our
study is the number of tested patients. On the one hand,
the decision to focus on a selected population of patients
(i.e. the ones with a known TDP-43-related pathogenic
mutation) increased the likelihood that the suspected
positive CSF really contained TDP-43 seeds. On the other
hand, since these mutations are quite rare, it reduced our
sample size. Even with this limitation, we considered this
approach as the most efficient in the adaptation of this
technology to TDP-43. In conclusion, we described a ro-
bust protocol for large-scale production of recombinant
TDP-43 and for its use as a substrate in the RT-QuIC re-
action. Our data on TDP-43 RT-QuIC represent a proof-
of-concept of its potential for the detection of TDP-43
pathological aggregates. Together with prion, amyloid b,
tau and a-syn RT-QuIC assays, a further optimization of
the presented TDP-43 RT-QuIC protocol would increase
the opportunity to perform the earliest and most accurate
diagnosis at a single patient level.
Supplementary material
Supplementary material is available at Brain
Communications online.
Acknowledgements
The authors acknowledge F. Ansaloni, Scuola Internazionale
Superiore di Studi Avanzati (SISSA), for his technical help in
data analysis and E. De Cecco, SISSA, for providing human
recombinant a-synuclein and tau proteins.
Funding
C.S. and G.L. received Scuola Internazionale Superiore di
Studi Avanzati intramural funding for this study. This study
was supported by the Italian Ministry of Health (Ricerca
Corrente): L.B., R.G. and F.M. This study was also supported
in part by the Italian Ministry of Health (GR-2013-02355724
to F.M. and GR-2013-02355764 to V.S.). The Association
for Frontotemporal Degeneration Susan Marcus Memorial
Fund Clinical Research Pilot Grant awarded to P.C.
Competing interests
The authors report no competing interests.
References
Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R,
et al. TDP-43 immunoreactivity in hippocampal sclerosis and
Alzheimer’s disease. Ann Neurol 2007; 61: 435–45.
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al.
TDP-43 is a component of ubiquitin-positive tau-negative inclusions
in frontotemporal lobar degeneration and amyotrophic lateral scler-
osis. Biochem Biophys Res Commun 2006; 351: 602–11.
Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya
K, et al. Phosphorylated TDP-43 in Alzheimer’s disease and demen-
tia with Lewy bodies. Acta Neuropathol 2009; 117: 125–36.
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B,
et al. Criteria for the diagnosis of corticobasal degeneration.
Neurology 2013; 80: 496–503.
Ayers JI, Cashman NR. Prion-like mechanisms in amyotrophic lateral
sclerosis. Handb Clin Neurol 2018; 153: 337–54.
Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015;
386: 1672–82.
Barghorn S, Biernat J, Mandelkow E. Purification of recombinant tau
protein and preparation of Alzheimer-paired helical filaments
in vitro. Methods Mol Biol 2005; 299: 35–51.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC,
et al. Clinical and biomarker changes in dominantly inherited
Alzheimer’s disease. N Engl J Med 2012; 367: 795–804.
Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal
fragments in ALS and FTLD. Front Neurosci 2019; 13: 335.
Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ,
Tredici KD. Amyotrophic lateral sclerosis—a model of corticofugal
axonal spread. Nat Rev Neurol 2013; 9: 708–14.
Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL,
Toledo JB, et al. Sequential distribution of pTDP-43 pathology in
behavioral variant frontotemporal dementia (bvFTD). Acta
Neuropathol 2014; 127: 423–39.








s/article/2/2/fcaa142/5905472 by guest on 15 O
ctober 2020
Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of
Neurology Research Group on Motor Neuron. El Escorial revisited:
revised criteria for the diagnosis of amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–9.
Budini M, Buratti E, Stuani C, Guarnaccia C, Romano V, Conti LD,
et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) ag-
gregation based on its C-terminal Gln/Asn-rich region. J Biol Chem
2012; 287: 7512–25.
Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S,
et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-
synucleinopathies. Ann Clin Transl Neurol 2016; 3: 812–8.
Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a
TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol 2018;
55: 7789–801.
Franceschini A, Baiardi S, Hughson AG, McKenzie N, Moda F, Rossi
M, et al. High diagnostic value of second generation CSF RT-QuIC
across the wide spectrum of CJD prions. Sci Rep 2017; 7: 10655.
Freeman SH, Spires-Jones T, Hyman BT, Growdon JH, Frosch MP.
TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp
Neurol 2008; 67: 62–7.
Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A
seeding reaction recapitulates intracellular formation of Sarkosyl-in-
soluble transactivation response element (TAR) DNA-binding pro-
tein-43 inclusions. J Biol Chem 2011; 286: 18664–72.
Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK,
et al. Pathological 43-kDa transactivation response DNA-binding
protein in older adults with and without severe mental illness. Arch
Neurol 2010; 67: 1238–50.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M,
Cappa SF, et al. Classification of primary progressive aphasia and
its variants. Neurology 2011; 76: 1006–14.
Groveman BR, Orru CD, Hughson AG, Raymond LD, Zanusso G,
Ghetti B, et al. Rapid and ultra-sensitive quantitation of disease-
associated alpha-synuclein seeds in brain and cerebrospinal fluid by
alphaSyn RT-QuIC. Acta Neuropathol Commun 2018; 6: 7.
Huang C, Ren G, Zhou H, Wang CC. A new method for purification
of recombinant human alpha-synuclein in Escherichia coli. Protein
Expr Purif 2005; 42: 173–7.
Jiang LL, Che MX, Zhao J, Zhou CJ, Xie MY, Li HY, et al. Structural
transformation of the amyloidogenic core region of TDP-43 protein
initiates its aggregation and cytoplasmic inclusion. J Biol Chem
2013; 288: 19614–24.
Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD.
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral
sclerosis-linked mutations accelerate aggregation and increase tox-
icity. J Biol Chem 2009; 284: 20329–39.
Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD,
Petrucelli L, et al. Updated TDP-43 in Alzheimer’s disease staging
scheme. Acta Neuropathol 2016; 131: 571–85.
Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in fila-
mentous neuronal inclusions in various neurodegenerative diseases.
Acta Neuropathol 2008; 116: 205–13.
Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in
ALS and FTD: disrupted RNA and protein homeostasis. Neuron
2013; 79: 416–38.
Mackenzie IR, Neumann M. Molecular neuropathology of frontotem-
poral dementia: insights into disease mechanisms from postmortem
studies. J Neurochem 2016; 138: 54–70.
Maniecka Z, Polymenidou M. From nucleation to widespread propa-
gation: a prion-like concept for ALS. Virus Res 2015; 207: 94–105.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s dis-
ease: recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–9.
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC,
Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degen-
eration and amyotrophic lateral sclerosis. Science 2006; 314: 130–3.
Ng AS, Rademakers R, Miller BL. Frontotemporal dementia: a bridge
between dementia and neuromuscular disease. Ann NY Acad Sci
2015; 1338: 71–93.
Nonaka T, Hasegawa M. TDP-43 Prions. Cold Spring Harb Perspect
Med 2018; 8: a024463.
Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi
T, et al. Prion-like properties of pathological TDP-43 aggregates
from diseased brains. Cell Rep 2013; 4: 124–34.
Orru CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groveman
BR, et al. A test for Creutzfeldt-Jakob disease using nasal brushings.
N Engl J Med 2014; 371: 519–29.
Orru CD, Groveman BR, Hughson AG, Zanusso G, Coulthart MB,
Caughey B. Rapid and sensitive RT-QuIC detection of human
Creutzfeldt-Jakob disease using cerebrospinal fluid. MBio 2015; 6:
e02451–14.
Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al.
Patient-derived frontotemporal lobar degeneration brain extracts in-
duce formation and spreading of TDP-43 pathology in vivo. Nat
Commun 2018; 9: 4220.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Grossman M, on behalf of the International bvFTD Criteria
Consortium (FTDC), et al. Sensitivity of revised diagnostic criteria
for the behavioural variant of frontotemporal dementia. Brain 2012;
135: e214.
Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focal-
ity, and spread: deconstructing motor neuron degeneration.
Neurology 2009; 73: 805–11.
Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of amyo-
trophic lateral sclerosis and its variants. Neurol Clin 2015; 33:
855–76.
Saijo E, Ghetti B, Zanusso G, Oblak A, Furman JL, Diamond MI,
et al. Ultrasensitive and selective detection of 3-repeat tau seeding
activity in Pick disease brain and cerebrospinal fluid. Acta
Neuropathol 2017; 133: 751–65.
Saini A, Chauhan VS. Delineation of the core aggregation sequences of
TDP-43 C-terminal fragment. Chembiochem 2011; 12: 2495–501.
Salvadores N, Shahnawaz M, Scarpini E, Tagliavini F, Soto C.
Detection of misfolded Abeta oligomers for sensitive biochemical
diagnosis of Alzheimer’s disease. Cell Rep 2014; 7: 261–8.
Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu
X, et al. Discriminating alpha-synuclein strains in Parkinson’s dis-
ease and multiple system atrophy. Nature 2020; 578: 273–7.
Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R,
Trenkwalder C, et al. Development of a biochemical diagnosis of
Parkinson disease by detection of alpha-synuclein misfolded aggre-
gates in cerebrospinal fluid. JAMA Neurol 2017; 74: 163–72.
Smethurst P, Newcombe J, Troakes C, Simone R, Chen YR, Patani R,
et al. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis
2016; 96: 236–47.
Tsermentseli S, Leigh PN, Goldstein LH. The anatomy of cognitive im-
pairment in amyotrophic lateral sclerosis: more than frontal lobe
dysfunction. Cortex 2012; 48: 166–82.
Turner MR, Al-Chalabi A, Chio A, Hardiman O, Kiernan MC,
Rohrer JD, et al. Genetic screening in sporadic ALS and FTD.
J Neurol Neurosurg Psychiatry 2017; 88: 1042–4.
Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A,
et al. Incidence and extent of TDP-43 accumulation in aging human
brain. Acta Neuropathol Commun 2015; 3: 35.
van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR,
Verbeek MM. alpha-Synuclein real-time quaking-induced conversion
in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann
Neurol 2019; 85: 777–81.
Walker LC, Jucker M. Neurodegenerative diseases: expanding the
prion concept. Annu Rev Neurosci 2015; 38: 87–103.
Wickham H. ggplot2: elegant graphics for data analysis. Berlin:
Springer; 2009.








s/article/2/2/fcaa142/5905472 by guest on 15 O
ctober 2020
